Aflac Incorporated
Aflac Incorporated Q2 FY26 Results — Earnings Call Analysis
Q2 FY26 earnings call: what management said on revenue, margins and capex.
Top 4 Insurance companies on management guidance
See the sector's top 10 — free with your mobile number.
Aflac Incorporated Q2 FY26 key numbers
- Revenue
- Japan’s earned premium growth is currently negative 1-2%; flat to modest growth expected when sales reach about JPY 90 billion to offset lapsation.
As stated in Aflac Incorporated's Q2 FY26 earnings call transcript · published 29 May 2026. Reported figures, not investment advice.
The short version
- Japan sales target for 2026 is around JPY 80 billion, slightly higher than 2025’s JPY 74 billion (Dan Amos, Page 12). - Japan's new cancer product and medical product sales showed strong growth in Q1, encouraging outlook for Aflac Japan (Virgil Miller, Page 12). - Aflac Japan expects sales of cancer insurance products in 2026 to be equivalent to 2025, supported by concurrent selling of multiple products (Koichiro Yoshizumi, Page 6). - Japan’s earned premium growth is currently negative 1-2%; flat to modest growth expected when sales reach about JPY 90 billion to offset lapsation (Page 9). - U.S. - Daniel Amos expects Japan sales to be closer to JPY 80 billion in 2026, higher than 2025's JPY 74 billion, indicating growth ambition.
From Aflac Incorporated's Q2 FY26 earnings-call transcript · updated 29 May 2026.
Revenue & Sales Performance
- Japan sales target for 2026 is around JPY 80 billion, slightly higher than 2025’s JPY 74 billion (Dan Amos, Page 12).
- Japan's new cancer product and medical product sales showed strong growth in Q1, encouraging outlook for Aflac Japan (Virgil Miller, Page 12).
- Aflac Japan expects sales of cancer insurance products in 2026 to be equivalent to 2025, supported by concurrent selling of multiple products (Koichiro Yoshizumi, Page 6).
- Japan’s earned premium growth is currently negative 1-2%; flat to modest growth expected when sales reach about JPY 90 billion to offset lapsation (Page 9).
2 more points from Aflac Incorporated's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Aflac Incorporated said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Aflac is investing in improving and enhancing its enrollment process to ease onboarding for new agents, helping them sell quickly and be productive early.
- The company is investing in innovative products and technology, especially focused on group product offerings catering to smaller employee groups.
- External reinsurance deals are pursued as an add-on strategy to grow business and earnings power with good IRRs, diversify earnings streams, and risk profiles without materially consuming capital or affecting shareholder returns.
- No current plans to increase leverage; however, there is flexibility to deploy significant capital and liquidity for operations, shareholder returns, or strategic investments like reinsurance deals.
2 more points from Aflac Incorporated's call on capex
Create a free account to keep reading this call
Top-ranked in Insurance
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Aflac Incorporated said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Daniel Amos indicated a target sales figure of around JPY 80 billion for Japan in 2026, higher than 2025's JPY 74 billion, suggesting an expectation of increased orderbook/sales.
- Max Broden confirmed JPY 90 billion in sales is needed for flat premium growth in Japan, highlighting that current levels are below that but expected to improve.
- Virgil Miller noted strong sales growth in new cancer and medical products in Japan Q1, contributing positively to orderbook.
- Aflac Japan has introduced multiple products being sold concurrently, which supports a healthy sales pipeline.
2 more points from Aflac Incorporated's call on order book
Create a free account to keep reading this call
What the Q2 FY26 call signalled
1 of 5 strong
Continue your research
Others in Insurance this season
- American Financial Group, Inc. (Q2 FY26)
American Financial Group, Inc. Q2 FY26 quarterly results analysis. Crop insurance gross written premium expected to be flat; net written premiums projected to i
- Erie Indemnity Company (Q2 FY26)
Erie Indemnity Company Q2 FY26 quarterly results analysis. Erie expects continued rollout and expansion of Erie Secure Auto into additional states this year, fo
- CNA Financial Corporation (Q2 FY26)
CNA Financial Corporation Q2 FY26 quarterly results analysis. Net written premium growth was 1% in Q1 2026, with significant variation by segment and class. Mar
- RenaissanceRe Holdings Ltd. (Q2 FY26)
RenaissanceRe Holdings Ltd. Q2 FY26 quarterly results analysis. New demand at midyear renewals is increasing, now estimated closer to $15 billion for U.S. Marke
Potential multibaggers · Q2 FY27
Potential multibaggers in Insurance
on management's own guidance
- Niva Bupa Health Insurance Company LtdGood growth2
- Max Financial Services LtdGood growth1
- Medi Assist Healthcare Services LtdGood growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Aflac Incorporated and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Aflac Incorporated Q2 FY26 results?
- Japan sales target for 2026 is around JPY 80 billion, slightly higher than 2025’s JPY 74 billion (Dan Amos, Page 12). - Japan's new cancer product and medical product sales showed strong growth in Q1, encouraging outlook for Aflac Japan (Virgil Miller, Page 12). - Aflac Japan expects sales of cancer insurance products in 2026 to be equivalent to 2025, supported by concurrent selling of multiple products (Koichiro Yoshizumi, Page 6). - Japan’s earned premium growth is currently negative 1-2%; flat to modest growth expected when sales reach about JPY 90 billion to offset lapsation (Page 9). - U.S. - Daniel Amos expects Japan sales to be closer to JPY 80 billion in 2026, higher than 2025's JPY 74 billion, indicating growth ambition.
What is Aflac Incorporated share price analysis?
Aflac Incorporated currently shows a neutral. The stock trades at a P/E of 13.4 with a market cap of $57,327. Investors should review the full earnings analysis for detailed insights.
Is Aflac Incorporated planning capital expenditure?
- Aflac is investing in improving and enhancing its enrollment process to ease onboarding for new agents, helping them sell quickly and be productive early.
Keep Aflac Incorporated on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.